Swiss biotech trusts resilient after recent sell-off – Swiss-listed biotech investment trusts, HBM Healthcare Investments (HBMN.S) and BB Biotech (BBB.S), have fared by far the best among all the sector specialist closed-end collective vehicles in the wake of the global market sell-off in recent days. All 13 trusts in the group monitored by Marten & Co have seen a fall […]
BB Biotech tops biotech trust league in January Swiss-listed BB Biotech (BBB), managed by Bellevue Asset Management, was the best performing biotech-specialist investment trust in January, achieving a 4.8% rise in sterling-denominated NAV total return. Furthermore, with a tightening of its discount to NAV, BB biotech saw a 10.4% rise in its sterling-translated share price over […]
HBM Healthcare tops biotech trust league in 2017 Swiss-listed HBM Healthcare Investments (HBMN.S) can claim to have been the best performing biotech-specialist closed-end fund in 2017, according to an analysis by Marten & Co. The CHF1.1bn trust run by Swiss healthcare investment specialist HBM saw its share price rise from CHF99 to CHF134 last year […]
Biotech bellwether Celgene to report key update next week Investors in the main sector specialist investment trusts should watch for an important update from Celgene early next week at the annual JP Morgan Healthcare Conference, the largest and most important investor event in the sector. The US biotech group is expected to “pre-announce” Q4 sales […]
Key guidance expected for biotech trust favourite Biogen Biogen, the neurology-focused US biotech giant and a key holding for several of the UK’s sector specialist investment trusts, will provide a closely-watched update for investors at next week’s JP Morgan Healthcare conference that could be critical to its 2018 outlook. Biogen’s CEO will present at the conference, […]
Pacific Horizon (PHI), managed by Ewan Markson-Brown (pictured), has announced its interim results for the six months ended 31 January 2017. During the period, the Trust’s NAV total return was 9.7%. The share price total return was 8.0% as the discount widened from 10.1% to 11.4%. The Trust says that, over the same period the […]
Over the year ended 30 June 2016, the sterling return of the MSCI All Countries World Index was 13.3% JPMorgan Global Growth & Income’s total return on net assets was lower than the benchmark, at 8.2%. There was a sharp widening of the discount from 6.9% at the start of the year to 14.4%, notwithstanding an active policy […]
The Board of International Biotechnology Trust has announced two proposals which it believes will be of benefit to shareholders and potential investors. These include the introduction of dividend payments and amendments to International Biotechnology Trust’s investment policy to allow it to invest in unquoted funds. Both proposals will be subject to shareholder approval at a […]
Worldwide Healthcare reports that, over the year ended 31 March 2016, the company’s net asset value per share total return was -9.0% and the share price total return was -10.5%, both underperforming the Company’s benchmark, the MSCI World Health Care Index on a net total return, sterling adjusted basis, which fell by 5.4%. Total dividend […]
LONDON (Alliance News) – British & American Investment Trust PLC, Biotech Growth Trust PLC, and International Biotechnology Trust PLC were among the best-performing London-listed investment companies in May, according to research firm QuotedData, which said there was a “small rally” in the biotech and healthcare sector that month. You can read the rest of the […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated
